

Gastrointestinal, Hepatobiliary, and Pancreatic Pathology

Perturbations in Ataxia Telangiectasia Mutant Signaling Pathways After Drug-Induced Acute Liver Failure and Their Reversal During Rescue of Animals by Cell Therapy

Sriram Bandi, Brigid Joseph, Ekaterine Berishvili, Rohit Singhania, Yao-Ming Wu, Kang Cheng, and Sanjeev Gupta

From the Departments of Medicine and Pathology, Marion Bessin Liver Research Center, Diabetes Center, Cancer Center, Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, and Institute for Clinical and Translational Research, Albert Einstein College of Medicine, Bronx, New York

Superior insights into molecular mechanisms of liver failure, which are not fully understood, will help strategies for inducing liver regeneration. We examined hepatotoxic mechanisms in mice homozygous for the severe combined immune deficiency mutation in the protein kinase, DNA-activated, catalytic polypeptide. Mice were treated with rifampicin, phenytoin, and monocrotaline. The ensuing acute liver failure was characterized by serological, histological, and mRNA studies. Subsequently, we studied whether transplantation of hepatocytes could rescue animals with liver failure. We found extensive liver damage in these animals, with mortality over several days. The expression of multiple hepatic genes was rapidly altered, including those representing pathways in oxidative/metabolic stress, inflammation, DNA damage-repair, and ataxia telangiectasia mutant (*Atm*) signaling pathways. This led to liver cell growth arrest involving cyclin-dependent kinase inhibitor 1A. Transplantation of hepatocytes with microcarriers in the peritoneal cavity efficiently rescued animals with liver failure. Molecular abnormalities rapidly reversed, including in hepatic *Atm* and downstream signaling pathways; and residual hepatocytes overcame cyclin-dependent kinase inhibitor 1A-induced cell growth arrest. Reseeding of the liver with transplanted hepatocytes was not required for rescue because native hepatocytes overcame cell growth-arrest to regenerate the liver. This likely resulted from paracrine signaling from hepatocytes in the peritoneal cavity. We concluded that *Atm* signaling

played critical roles in the pathological features of liver failure. These studies should help redirect examination of pathophysiologic and therapeutic mechanisms in liver failure. (Am J Pathol 2011, 178:161–174; DOI: 10.1016/j.ajpath.2010.11.001)

Drug-induced liver injury (DILI) often results in acute liver failure (ALF).¹ Acetaminophen (APAP) is the leading offender in causing ALF; however, despite extensive work, mechanisms of DILI by APAP are incompletely understood.^{2–5} The identification of molecular pathways initiating or amplifying DILI will be highly significant for drug development and for preventing and/or treating ALF. After exposure to hepatotoxic drugs, perturbations in cell stress and toxicity pathways assume prominence. However, more information is required regarding intracellular signaling pathways that impart susceptibility to DILI. Similarly, more information is required regarding failure of liver regeneration in ALF. Nevertheless, establishing these mechanisms has been difficult in the available animal models of ALF. For instance, after exposure to toxic drugs or chemicals, some animals may exhibit rapid and irreversible mortality (eg, within 24–30 hours after APAP), whereas other animals may recover spontaneously.

Supported in part by the NIH (grants R01 DK071111 and P30-DK41296) and by a Druckenmiller fellowship from the New York Stem Cell Foundation (S.B.).

Accepted for publication September 14, 2010.

A guest editor acted as editor-in-chief for this manuscript. No person at Thomas Jefferson University or Albert Einstein College of Medicine was involved in the peer review process or final disposition of this article.

Current address of E.B., Institute of Experimental Medicine, Tbilisi State Medical University, Tbilisi, Republic of Georgia; of R.S., St Luke's Hospital, New York, New York; of Y.M.W., Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; and of K.C., Long Island Jewish Medical Center, New Hyde Park, New York.

Address reprint requests to Sanjeev Gupta, M.D., Albert Einstein College of Medicine, Ullmann Bldg, Room 625, 1300 Morris Park Ave, Bronx, NY 10461. E-mail: sanjvgupta@pol.net or sanjeev.gupta@einstein.yu.edu.

Therefore, animal models more faithfully reproducing the human condition, in which mortality after onset of ALF occurs over much longer periods,¹ will be invaluable.

Recently, studies of DILI in healthy C57BL/6 mice showed that the antitubercular drug, rifampicin (Rif), the anticonvulsant agent, phenytoin (Phen), and the plant-derived pyrrolizidine alkaloid, monocrotaline (MCT), produced liver damage synergistically.⁶ However, when we sought to reproduce this Rif-Phen-MCT-induced liver injury in mice with severe combined immune deficiency (SCID) mutation in the protein kinase, DNA-activated, catalytic polypeptide (*Prkdc^{scid}/J*), we instead observed ALF, with mortality over several days. Characterization of the nature of this liver injury and analysis of underlying molecular mechanisms demonstrated that strain-specific regulation of gene expression accounted for differences in outcomes of Rif-Phen-MCT-induced hepatotoxicity in C57BL/6 mice versus these NOD/SCID (C3H/He) mice. Studies of cell stress and toxicity pathways identified changes in ataxia telangiectasia mutant (*Atm*) signaling in ALF. Depletion of *Atm* after Rif-Phen-MCT led to alterations in downstream signaling, including DNA damage/repair pathways, which culminated in cyclin-dependent kinase inhibitor 1A (*p21*)-mediated liver cell growth arrest and accounted for impairment in liver regeneration. Previously, these intracellular cell signaling and hepatocellular growth-arrest mechanisms had not been identified in DILI.²⁻⁵

Recapitulation of multiple aspects of ALF in humans, including mortality several days after DILI, permitted us to examine therapeutic mechanisms. This was important because mortality in people with ALF remains extremely high (ie, 50%-70%). Orthotopic liver transplantation (OLT) constitutes the only definitive treatment for ALF. However, severe shortages of donor livers and technical complexities restrict OLT. Therefore, alternatives, such as cell therapy, are of much interest.⁷ Conceptually, if cell therapy would prolong life through provision of hepatic support, people with ALF could be bridged to OLT. On the other hand, if reseeded of the liver with healthy transplanted cells would promote liver regeneration, OLT could be avoided altogether. Despite multiple cell transplantation studies in various models of ALF, these key mechanisms had not been effectively addressed.⁸

Previous studies^{8,9} established that transplantation of hepatocytes into hepatic sinusoids was most effective for survival and function of transplanted cells in the liver. However, because the capacity of the hepatic vascular bed for transplanted cells is small,¹⁰ this posed questions about the feasibility of significant hepatic support by this method. Cell transplantation in liver sinusoids may even be undesirable in ALF because occlusion of blood flow by transplanted cells might worsen hepatic injury.¹¹⁻¹⁴ Moreover, transplanted hepatocytes integrate in liver parenchyma over several days and take far longer to proliferate,^{6,8} casting doubt on the importance of reseeded of the liver in ALF. By contrast, spacious extrahepatic sites (eg, the peritoneal cavity) may accommodate many transplanted cells.^{9,15,16} With appropriate scaffolds, transplanted hepatocytes may engraft in the peritoneal cavity and express metabolic or synthetic functions. Because NOD/SCID mice with Rif-Phen-MCT-induced ALF tolerated cell transplantation

in the liver and peritoneal cavity, we were able to study cell therapy mechanisms in ALF.

Materials and Methods

Drugs, chemicals, and reagents were obtained from Sigma Chemical Co, St Louis, MO.

Animals

The Animal Care and Use Committee of Albert Einstein College of Medicine, Bronx, NY, approved protocols according to the National Research Council's *Guide for the Care and Use of Laboratory Animals*.¹⁷ Male NOD.CB17-*Prkdc^{scid}/J* (NOD/SCID) mice, aged 6 to 7 weeks; B6.129S7-Gt(Rosa)26Sor/J (Rosa26) mice, and C57BL/6-TgCAG-EGFP/10sb/J [green fluorescent protein (GFP)] mice were obtained from Jackson Laboratories, Bar Harbor, ME. The NOD.CB17-*Prkdc^{scid}/J* mice were in a C3H/HeJ background. Fischer 344 (F344) rats and C57BL/6 mice were obtained from the National Cancer Institute-Frederick Animal Production Program, Bethesda, MD. To induce ALF, NOD/SCID mice were treated for 3 days by i.p. injections (in normal saline) of Rif (75 mg/kg) and Phen (30 mg/kg), followed on day 4 by MCT (100-150 mg/kg), as previously described.⁶

Cell Isolation and Transplantation

Hepatocytes were isolated from healthy F344 rats, C57BL/6 mice, GFP mice, or Rosa26 mice by collagenase perfusion of the liver, as previously described.^{6,8} Cell viability was tested by trypan blue dye exclusion and was 80% or greater. For cell transplantation studies, NOD/SCID mice treated with Rif-Phen-MCT were given 5×10^6 to 50×10^6 cells i.p., along with 1-ml microcarriers (Cytodex 3; Amersham Biosciences Corp, Piscataway, NJ) in a total volume of 1.2 to 1.5 ml. In early studies, hepatocytes from C57BL/6 mice were transplanted into NOD/SCID mice with induction of ALF. These animals were studied for reversal of mortality over 2 weeks versus untreated mice with ALF. To determine whether, after i.p. transplantation, donor cells were distributed to various organs, we transplanted GFP transgenic mouse hepatocytes into NOD/SCID mice with ALF, followed by analysis of the presence of transplanted cells in the peritoneal cavity, liver, spleen, and lungs after 24 hours, 48 hours, and 7 days by tissue staining for GFP. To demonstrate the benefits of cell therapy in ALF, we performed studies in NOD/SCID mice with ALF, followed by transplantation of C57BL/6 mouse or F344 rat hepatocytes, ranging from 5×10^6 to 50×10^6 cells. Animal outcomes were analyzed over time, including after early (1-3 days) and later (4 days to 12 weeks) times. In some mice, 2×10^6 Rosa26 cells were transplanted simultaneously via the spleen for deposition into the liver, as previously described.¹³ Cells were transplanted within 2 hours after isolation. Multiple groups of animals were established, as indicated in individual studies, including control mice treated




Figure 1. Hepatic injury in NOD/SCID mice. Vehicle-treated control mice and mice treated with Rif and Phen for 3 days, followed by either 125- or 150-mg/kg MCT, are shown. **A:** Serum ALT levels. **B:** Serum bilirubin levels. **C:** Grade of encephalopathy. **D:** Survival curves in animals. **E** through **H:** Normal liver histological features in a vehicle-treated control mouse (**E**), whereas mice 1 day (**F**), 4 days (**G**), and 7 days (**H**) after Rif, Phen, and 125-mg/kg MCT showed loss of liver parenchyma (pink areas without blue nuclei). Original magnification, $\times 100$. Scale bar = 100 μm (hematoxylin-eosin stain).

with vehicle and microcarriers alone. All analyses were with groups of three to six mice or more. Untreated control mice were included as necessary.

Quantitative Real-Time PCR

RNA was extracted from three animals per experimental condition. Total RNA was extracted by Trizol solution (Invitrogen Corp, Carlsbad, CA), cleaned with a kit (RNeasy Kit), and treated with DNase (Qiagen Corp, Valencia, CA). cDNA was prepared from 1 μg of total RNA with a kit (First Strand cDNA Synthesis Kit; C-01, SA Biosciences, Frederick, MD). The expression of 84 genes was studied by RT² (Real-Time SYBR Green PCR Array; Mouse Stress and Toxicity Pathway Finder, SA Biosciences, Frederick, MD) in an instrument (ABI 7000; Applied Biosystems, Foster City, CA). Amplifications were in 25 μL , with denaturation for 10 minutes at 95°C, 40 cycles for 15 seconds at 95°C, and annealing for 60

seconds at 60°C. Gene expression was normalized to β -actin in each sample before comparisons. Threshold cycle values were determined with computer software (ABI Prism 7000 SDS software). Fold changes in gene expression were analyzed as follows: $2^{(-\Delta\Delta\text{Threshold Cycle})}$. Genes of interest were selected based on a 2-fold change or greater, either upward or downward, with $P < 0.05$ in group comparisons. Curated gene pathways of interest were mapped by software (PathwayStudio5.0; Ariadne Genomics, Rockville, MD).

Cytochrome P450 3a4 Expression

Tissue samples were dounce homogenized in 0.25-mol/L sucrose, 10-mmol/L Tris hydrochloride (pH 7.5), and protease inhibitor cocktail (Calbiochem 539134; EMD Biosciences Inc, San Diego, CA). Lysates were centrifuged at $2000 \times g$ for 25 minutes and then at $100,000 \times g$ for 1 hour at 4°C. Pellets were sonicated, and 75 μg of total proteins was separated in 10% SDS-polyacrylamide gel electrophoresis. After transfer, nitrocellulose membranes were incubated for 1 hour with anti-cytochrome P450 (CYP) 3A4 (1:4000, A4100; Xenotech, Lenexa, KA), followed by peroxidase-conjugated anti-rabbit IgG (1:5000, 321804; Amersham Biosciences, Piscata-




Figure 2. Hepatic apoptosis and proliferation after drug-induced damage in NOD/SCID mice. The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assays (**A**, **C**, **E**, and **G**) and Ki-67 immunostaining (**B**, **D**, **F**, and **H**) are shown. **A** and **B:** Normal liver with absence of TUNEL or Ki-67 expression. **C:** The DNase-treated liver as a positive control for TUNEL. **D:** Mouse liver 40 hours after partial hepatectomy showing widespread Ki-67 expression in hepatocytes. **E** and **F:** Infrequent TUNEL-positive cells (**E**) and hepatocytes with Ki-67 (**F**) 3 days after Rif, Phen, and 125-mg/kg MCT. **G:** Infrequent TUNEL-positive cells 7 days after Rif, Phen, and MCT. **H:** Ki-67 expression in periportal hepatocytes 8 days after Rif, Phen, and MCT. Original magnification, $\times 200$. Scale bar = 100 μm (left, methylgreen counterstain; right, toluidine blue counterstain).

Table 1. Differences in Baseline Expression Levels of Genes in Healthy NOD/SCID Mice Versus C57BL/6 Mice

Gene description	Gene symbol	Expression level for NOD/SCID/C57/BL6
Oxidative or metabolic stress		
Up-regulated		
Cytochrome P450, family 2, subfamily a, polypeptide 5	<i>Cyp2a5</i>	741.00
Cytochrome P450, family 2, subfamily b, polypeptide 10	<i>Cyp2b10</i>	205.00
Cytochrome P450, family 2, subfamily b, polypeptide 9	<i>Cyp2b9</i>	46.00
Cytochrome P450, family 2, subfamily c, polypeptide 29	<i>Cyp2c29</i>	39.00
Flavin-containing monooxygenase 4	<i>Fmo4</i>	2.30
Glutathione-S-transferase, μ 3	<i>Gstm3</i>	3.38
Superoxide dismutase 2, mitochondrial	<i>Sod2</i>	177.00
Down-regulated		
Cytochrome P450, family 1, subfamily a, polypeptide 1	<i>Cyp1a1</i>	0.14
Cytochrome P450, family 1, subfamily b, polypeptide 1	<i>Cyp1b1</i>	0.02
Cytochrome P450, family 3, subfamily a, polypeptide 11	<i>Cyp3a11</i>	0.15
Cytochrome P450, family 4, subfamily a, polypeptide 10	<i>Cyp4a10</i>	0.20
Cytochrome P450, family 4, subfamily a, polypeptide 14	<i>Cyp4a14</i>	0.01
Flavin-containing monooxygenase 1	<i>Fmo1</i>	0.21
Flavin-containing monooxygenase 5	<i>Fmo5</i>	0.33
Glutathione peroxidase 1	<i>Gpx1</i>	0.12
Glutathione reductase	<i>Gsr</i>	0.29
Glutathione-S-transferase, 1	<i>Gstm1</i>	0.20
Heme oxygenase (decycling) 2	<i>Hmox2</i>	0.16
Superoxide dismutase 1, soluble	<i>Sod1</i>	0.00
Heat shock		
Up-regulated		
Heat shock protein 41	<i>Hspa4</i>	7.90
Down-regulated		
DnaJ (Hsp40) homolog, subfamily A, member 1	<i>Dnaja1</i>	0.10
Hsp 1	<i>Hspa1b</i>	0.00
Hsp 1-like	<i>Hspa1l</i>	0.09
Hsp 5	<i>Hspa5</i>	0.16
Hsp 8	<i>Hspa8</i>	0.30
Hsp β -1	<i>Hspb1</i>	0.03
Hsp 1 (chaperonin)	<i>Hspd1</i>	0.19
Hsp 1 (chaperonin 10)	<i>Hspe1</i>	0.35
Heat shock transcription factor 1	<i>Hsf1</i>	0.23
Proliferation and carcinogenesis		
Up-regulated		
Cyclin C	<i>Ccnc</i>	16.33
Cyclin D1	<i>Ccnd1</i>	20.25
Down-regulated		
Colony-stimulating factor 2 (granulocyte-macrophage)	<i>Csf2</i>	0.06
E2F transcription factor 1	<i>E2f1</i>	0.04
Early growth response 1	<i>Egr1</i>	0.50
Insulinlike growth factor binding protein 6	<i>Igfbp6</i>	0.33
Growth arrest and senescence		
Down-regulated		
Cyclin-dependent kinase inhibitor 1A (p21)	<i>Cdkn1a</i>	0.01
Transformed mouse 3T3 cell double minute 2	<i>Mdm2</i>	0.09
Tumor protein p53	<i>Trp53</i>	0.46
Inflammation		
Up-regulated		
Interleukin 1 β	<i>Il1b</i>	2.19
Down-regulated		
Chemokine (C-C motif) ligand 3	<i>Ccl3</i>	0.10
Chemokine (C-C motif) ligand 4	<i>Ccl4</i>	0.05
Chemokine (C-C motif) ligand 21	<i>Ccl21b</i>	0.07
Interleukin 6	<i>Il6</i>	0.12
Nuclear factor of κ light polypeptide gene enhancer in B-cell inhibitor, α	<i>Nfkbia</i>	0.34
Nitric oxide synthase 2, inducible, macrophage	<i>Nos2</i>	0.07
Serine (or cysteine) peptidase inhibitor, clade E, member 1	<i>Serpine1</i>	0.49
DNA damage and repair		
Up-regulated		
RAD50 homolog (<i>Saccharomyces cerevisiae</i>)	<i>Rad50</i>	3.54

(table continues)

Table 1. *Continued*

Gene description	Gene symbol	Expression level for NOD/SCID/C57/BL6
Down-regulated		
Ataxia telangiectasia mutated homolog (human)	<i>Atm</i>	0.50
Cyclin G1	<i>Ccng1</i>	0.50
DNA damage-inducible transcript 3	<i>Ddit3</i>	0.29
Excision repair cross complementing rodent repair deficiency, complementation group 1	<i>Ercc1</i>	0.22
RAD23 homolog A (<i>S cerevisiae</i>)	<i>Rad23a</i>	0.41
X-ray repair complementing defective repair in Chinese hamster cells 1	<i>Xrcc1</i>	0.20
X-ray repair complementing defective repair in Chinese hamster cells 4	<i>Xrcc4</i>	0.42
Apoptosis signaling		
Up-regulated		
Bcl2-like-1	<i>Bcl2l1</i>	4.20
Caspase 8	<i>Casp8</i>	19.65
Tumor necrosis factor receptor superfamily, member 1a	<i>Tnfrsf1a</i>	7.00
Down-regulated		
Annexin A5	<i>Anxa5</i>	0.16
Bcl2-associated X protein	<i>Bax</i>	0.10
Caspase 1	<i>Casp1</i>	0.16
Lymphotoxin α	<i>Lta</i>	0.08
TNFRSF1A associated via death domain	<i>Tradd</i>	0.13

NOD, natural-onset diabetes; SCID, severe combined immunodeficiency; Hsp, heat shock protein.

away, NJ) for 1 hour for enzymatic chemiluminescence. Blots were stained with ponceau red to verify equivalent protein loading.

Histological Studies

Liver samples were fixed in 10% formalin, and sections were stained with hematoxylin-eosin. Tissues were frozen in methylbutane to -80°C for 5- μm -thick cryosections. Bacterial β -galactosidase (LacZ), glycogen, and glucose-6-phosphatase were stained histochemically, as previously described.^{6,18} Immunostainings were for *p21* (1:50, sc-397; Santa Cruz Biotechnology Inc, Santa Cruz, CA), proliferation-related Ki-67 antigen (Ki-67) (1:1000, VP-K451; Vector Labs Inc, Burlingame, CA), heme oxygenase 1 (1:50, AB128; Chemicon International Inc, Temecula, CA), glutathione-S-transferase 1 (1:200, primary antibody in rabbit from Dr I. Listowski, Albert Einstein College of Medicine), *ATM* (1:150, AB370; Chemicon International Inc), oxidative DNA adducts on guanine residues (4359-MC-100; Trevigen Inc, Gaithersburg, MD), and CD11b (1:100 phycoerythrin-conjugated antibody, 553310; BD Pharmingen, San Diego, CA). Peroxidase-conjugated goat anti-mouse or anti-rabbit Igs (1:500 to 1:600 of No. 3682 and AO545, respectively; Sigma Chemical Co) were used with color development by diaminobenzidine (K3465; Dako Corp, Carpinteria, CA). In negative controls, primary antibodies were omitted. For Ki-67, the positive control was liver 40 hours after two-thirds partial hepatectomy. Apoptosis was shown with a kit (ApopTag Peroxidase In Situ Kit; Chemicon International Inc). For GFP staining, tissues were equilibrated in 30% sucrose and then frozen. Cryostat sections were fixed with 4% paraformaldehyde and blocked in 5% goat serum for incubation with rabbit anti-GFP (1:300; Molecular Probes, Eugene, OR) and then incubated with conjugated goat anti-rabbit IgG (Alexa Fluor 488; Molecular

Probes). Morphometric quantitation was in multiple sections per animal ($n = \geq 3$ per condition). Typically, 25 tissue sections were scored.

Outcomes in Animals with ALF

Mice were observed daily for grading of encephalopathy and for mortality. Encephalopathy was graded as follows: 0, normal behavior of animals; 1, decreased motor activity and lethargy; 2, sedated appearance and immobility or reticence to move in cages; and 3, comatose condition. The duration of survival was monitored for at least 2 weeks. Animal studies extended up to 12 weeks, with continued observation and blood and tissue sampling from some mice after 4, 8, and 12 weeks. Some animals were sacrificed for interval studies ($n = 3-6$), as described later.

Serological Assays

Serum samples were stored at -20°C for alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin measurements in automated clinical systems. Prothrombin time was measured by thromboplastin (Plastinex, 101158; Bio/Data Corp, Horsham, PA) with blood in 0.11-mol/L sodium citrate. Plasma was diluted in water (7:3, v/v). To 0.1-ml plasma, 0.2-ml thromboplastin reconstituted in water and preincubated with plasma at 37°C for 5 minutes was added and time to clotting was measured.

Statistical Analyses

Data are shown as mean \pm SD. Differences were analyzed by *t*-test, χ^2 test, analysis of variance with Holm-Sidak pairwise comparisons, or log-rank tests in survival curves by computer software (SigmaStat 3; Systat Soft-

ware Inc, Point Richmond, CA). $P < 0.05$ was considered significant.

Results

In the first set of studies, we characterized ALF in NOD/SCID mice. This was followed by cell transplantation studies in the next part to demonstrate mechanisms in the rescue of animals with ALF.

Characterization of ALF

We observed dose-dependent DILI in mice given fixed amounts of Rif (75 mg/kg) and Phen (30 mg/kg), followed by 100-, 125-, or 150-mg/kg MCT. The NOD/SCID mice tolerated Rif, Phen, and 100-mg/kg MCT without overt hepatotoxicity or liver necrosis. However, severe liver injury was evident after Rif plus Phen, followed by either 125- or 150-mg/kg MCT. Serum ALT and total bilirubin levels in mice treated with Rif, Phen, and 125-mg/kg MCT ($n = 30$) or Rif, Phen, and 150-mg/kg MCT ($n = 30$) showed significant changes compared with vehicle-treated mice ($n = 20$) (Figure 1, A and B). Serum ALT and total serum bilirubin levels were 58 ± 3 U/L and 0.3 ± 0.1 mg/dL, respectively, in control mice. By contrast, in mice 1, 2, 3, and 6 to 8 days after Rif, Phen, and 150-mg/kg MCT, serum ALT levels were 2350 ± 180 , 5500 ± 670 , 6380 ± 689 , and 4689 ± 300 U/L, respectively; and serum bilirubin levels were 1.1 ± 0.5 , 0.8 ± 0.4 , 3.0 ± 1.0 , and 2.5 ± 0.7 mg/dL, respectively ($P < 0.05$, analysis of variance with Holm-Sidak tests). Prothrombin time was prolonged by 2- to 4-fold above normal in drug-treated mice, reflecting severe liver injury. Virtually all mice exhibited encephalopathy 6 days after drugs, which was worse in mice given 150-mg/kg MCT (Figure 1C). Most mice were in grade 3 to 4 encephalopathy before death. As expected, vehicle-treated control mice remained alive and well, whereas extensive mortality was observed in drug-treated mice (Figure 1D). Analysis of mortality showed that after Rif, Phen, and 150-mg/kg MCT, 50% died in 5.5 days and 100% died in 7 days ($P < 0.05$, log-rank tests versus controls). The duration of survival was slightly longer after Rif, Phen, and 125-mg/kg MCT, with 40% dying by 5.5 days, 67% dying by 7 days, and 87% dying by 14 days ($P < 0.05$ versus controls and $P > 0.05$ versus 150-mg/kg MCT). In view of slightly longer survival in mice treated with 125-mg/kg MCT, we performed further studies of animals under this condition. Liver morphological features in control mice were normal (Figure 1E), although drug-treated mice showed extensive liver necrosis; 1 day after Rif, Phen, and 125-mg/kg MCT, 30% to 40% of the liver parenchyma was destroyed (Figure 1F). After 4 days, 50% to 70% of the liver parenchyma was lost (Figure 1G). This parenchymal loss continued, with 50% to 70% hepatic necrosis before death, typically after 6 to 9 days (Figure 1H).

The course of morphological changes agreed with abnormalities in liver test results, including prolongation of prothrombin time, encephalopathy, and mortality. We did

not observe proliferation of bile duct cells or appearance of other liver cell subpopulations (eg, oval cells), indicating that liver injury did not activate putative hepatic stem cells. The liver was not grossly infiltrated with inflammatory cells (eg, neutrophils, macrophages, eosinophils, or basophils), which represented the innate immune system. The NOD/SCID mice lacked T and B lymphocytes.

To determine the effects of Rif-Phen-MCT on liver cell turnover, we studied apoptosis and cell proliferation in multiple liver sections (Figure 2). In healthy control mice, only 0 to 1 apoptotic cell per liver section was found (Figure 2A). Apoptosis increased slightly in drug-treated mice, with 5 to 8 cells per section (Figure 2, C, E, and G). This mostly nonapoptotic injury was in agreement with extensive tissue necrosis. In healthy livers, we observed $<0.01\%$ cells with Ki-67, indicating little cell turnover (Figure 2B). By contrast, Ki-67 expression increased extensively after partial hepatectomy, as expected (Figure 2D). In drug-treated mice, hepatocytes in periportal areas expressed Ki-67 (Figure 2, F and H). Morphometry showed Ki-67 expression in $4\% \pm 3\%$ of hepatocytes in mice 1 to 3 days after ALF and in $7\% \pm 2\%$ of hepatocytes in mice 4 to 8 days after ALF ($P < 0.05$). This extent of hepatocellular proliferation was insufficient for restoring the liver and rescuing animals from ALF in most cases.

Liver Gene Expression in Healthy NOD/SCID and Healthy C57BL/6 Mice

To examine the basis for differences in DILI in NOD/SCID and C57BL/6 mice, we analyzed genes in stress and toxicity pathways. Of 84 such genes, expression of 15 (18%) was 2-fold or more higher and expression of 47 (56%) was 2-fold or more lower in NOD/SCID mice versus C57BL/6 mice (Table 1).

Several *Cyp* genes were expressed more in NOD/SCID mice compared with C57BL/6 mice (*Cyp2a5*, *Cyp2b10*, *Cyp2b9*, and *Cyp2c29*), whereas other *Cyp* genes were expressed at lower levels in NOD/SCID mice (*Cyp1a1*, *Cyp1b1*, *Cyp3a11*, *Cyp4a10*, and *Cyp4a14*), which reflected differences in metabolic activity or stress and toxicity conditions (Table 1). Similarly, genes involved in oxidative stress were either expressed more (eg, superoxide dismutase 2) or less (eg, superoxide dismutase 1) in NOD/SCID mice. Several heat shock protein (*Hsp*) genes were expressed at lower levels, although *Hspa4* was expressed at higher levels in NOD/SCID versus C57BL/6 mice, suggesting less hepatic preconditioning by environmental stresses (eg, lack of microbial expo-




Figure 3. Induction of hepatic *Cyp3a4* by Rif and Phen for 3 days in mice. Western blot showing *Cyp3a4* in NOD/SCID and C57BL/6 mice: lanes 1 and 2, drug-untreated controls; and lanes 3 and 4, after drug treatments.

Table 2. Gene Expression Levels in NOD/SCID Mice Treated by Rif-Phen-MCT Versus Healthy NOD/SCID Mice

Gene description	Gene symbol	NOD/SCID baseline	Time after drugs, days		
			1	3	7
Oxidative or metabolic stress					
Up-regulated					
Cytochrome P450, family 2, subfamily b, polypeptide 10	<i>Cyp2b10</i>	1.0	1.2*	5.0	1.1*
Cytochrome P450, family 3, subfamily a, polypeptide 11	<i>Cyp3a11</i>	1.0	2.8	1.8*	3.4
Glutathione peroxidase 2	<i>Gpx2</i>	1.0	4.2	2.0	4.1
Glutathione-S-transferase, μ 3	<i>Gstm3</i>	1.0	15.7	3.7	16.0
Heme oxygenase (decycling) 1	<i>Hmox1</i>	1.0	0.5*	5.2	0.5*
Down-regulated					
Cytochrome P450, family 1, subfamily b, polypeptide 1	<i>Cyp1b1</i>	1.0	0.3	0.7*	0.3
Cytochrome P450, family 2, subfamily a, polypeptide 5	<i>Cyp2a5</i>	1.0	0.3	0.1	0.3
Cytochrome P450, family 2, subfamily b, polypeptide 9	<i>Cyp2b9</i>	1.0	0.0	0.0	0.0
Cytochrome P450, family 4, subfamily a, polypeptide 10	<i>Cyp4a10</i>	1.0	0.1	0.1	0.1
Cytochrome P450, family 4, subfamily a, polypeptide 14	<i>Cyp4a14</i>	1.0	0.1	0.0	0.1
Cytochrome P450, family 7, subfamily a, polypeptide 1	<i>Cyp7a1</i>	1.0	0.1	0.0	0.1
Flavin-containing monooxygenase 1	<i>Fmo1</i>	1.0	0.8*	0.2	0.8*
Flavin-containing monooxygenase 4	<i>Fmo4</i>	1.0	0.4	0.2	0.4
Heat shock					
Up-regulated					
Hsp 1	<i>Hspb1</i>	1.0	3.5	27.4	3.6
Hsp 1-like	<i>Hspa1l</i>	1.0	2.0	0.4	2.4
Hsp 8	<i>Hspa8</i>	1.0	0.6*	2.4	0.0
Down-regulated					
DnaJ (Hsp40) homolog, subfamily A, member 1	<i>Dnaj1</i>	1.0	0.3	0.4	0.3
Hsp 1 (chaperonin)	<i>Hspd1</i>	1.0	0.0	0.5	0.3
Hsp 1 (chaperonin 10)	<i>Hspe1</i>	1.0	0.4	0.7	0.5
Proliferation and carcinogenesis					
Up-regulated					
E2F transcription factor 1	<i>E2f1</i>	1.0	2.4	0.7*	0.5*
Down-regulated					
Cyclin D1	<i>Ccnd1</i>	1.0	0.6*	0.1	0.5*
Early growth response 1	<i>Egr1</i>	1.0	0.3	9.9	0.2
Growth arrest and senescence					
Up-regulated					
Cyclin-dependent kinase inhibitor 1A (p21)	<i>Cdkn1a</i>	1.0	277.0	434.0	277.0
DNA damage-inducible transcript 3	<i>Ddit3</i>	1.0	1.2*	11.5	1.3*
Growth arrest and DNA damage-inducible 45 α	<i>Gadd45a</i>	1.0	0.8*	74.0	1.0*
Transformed mouse 3T3 cell double minute 2	<i>Mdm2</i>	1.0	9.3	4.4	6.2
Inflammation					
Up-regulated					
Chemokine (C-X-C motif) ligand 10	<i>Cxcl10</i>	1.0	0.7*	3.1	0.9*
Interleukin 6	<i>Il6</i>	1.0	0.8*	4.5	0.6*
Nitric oxide synthase 2, inducible, macrophage	<i>Nos2</i>	1.0	1.0*	5.7	0.8*
Serine (or cysteine) peptidase inhibitor, clade E, member 1	<i>Serpine1</i>	1.0	5.4	42.2	11.1
Down-regulated					
Interleukin 1 β	<i>Il1b</i>	1.0	0.0	0.6*	0.1
Interleukin 18	<i>Il18</i>	1.0	0.4	0.5*	0.4
DNA damage and repair					
Up-regulated					
Cyclin G1	<i>Ccng1</i>	1.0	8.8	4.3	8.4
Uracil DNA glycosylase	<i>Ung</i>	1.0	1.3*	2.5	1.4*
Down-regulated					
Ataxia telangiectasia mutated homolog (human)	<i>Atm</i>	1.0	0.4	0.1	0.6*
CHK2 checkpoint homolog (<i>Schizosaccharomyces pombe</i>)	<i>Chek2</i>	1.0	1.5*	0.2	1.7*
RAD50 homolog (<i>Saccharomyces cerevisiae</i>)	<i>Rad50</i>	1.0	0.6*	0.1	0.7*
X-ray repair complementing defective repair in Chinese hamster cells 4	<i>Xrcc4</i>	1.0	0.5	0.2	0.5
Apoptosis signaling					
Up-regulated					
Annexin A5	<i>Anxa5</i>	1.0	2.3	1.3*	2.8
Bcl2-associated X protein	<i>Bax</i>	1.0	3.1	0.6*	3.7
Bcl2-like-1	<i>Bcl2l1</i>	1.0	0.3	2.1	0.7*
Down-regulated					
Fas ligand (TNF superfamily, member 6)	<i>Fasl</i>	1.0	0.1	0.2	0.1
TNF (ligand) superfamily, member 10	<i>Tnfsf10</i>	1.0	0.2	0.1	0.3
TNFRSF1A-associated via death domain	<i>Tradd</i>	1.0	0.5*	0.2	0.5*

NOD, natural-onset diabetes; SCID, severe combined immunodeficiency; Rif, rifampicin; Phen, phenytoin; MCT, monocrotaline; NS, not significant; Hsp, heat shock protein; TNF, tumor necrosis factor.
 *Statistically not significant

tures under pathogen-free conditions). This seemed consistent with lower expression of inflammation-associated genes in NOD/SCID mice (eg, *Il6*, nitric oxide synthase, and C-C motif chemokines 3 and 4). By contrast, interleukin-1b was expressed at higher levels in NOD/SCID versus C57BL/6 mice, possibly secondary to T- and B-cell deficiency. Differences in apoptosis genes, some expressed at higher and others at lower levels in NOD/SCID mice, were of unclear significance, given that hepatic apoptosis was absent (Figure 2A).

If NOD/SCID mice were undergoing genotoxic liver injury, expression of relevant genes should have been altered. However, DNA damage/repair genes were expressed 2- to 5-fold less in NOD/SCID mice, including *Atm*, cyclin G, Chek 2, CHK2 checkpoint homolog 1, DNA damage-inducible transcript 3 (*Ddit3*), excision repair cross-complementing rodent repair deficiency, complementation group 1, RAD23 homolog A (*Saccharomyces cerevisiae*), X-ray repair complementing defective repair in Chinese hamster cells 1 (*Xrcc1*), and *Xrcc4* genes (Table 1). This agreed with lower basal hepatic genotoxicity in NOD/SCID mice compared with C57BL/6 mice. The significance of *Atm* expression became apparent in further studies (explained later). Among this group of DNA damage/repair genes, only RAD50 homolog (*S cerevisiae*), which repairs double-strand DNA breaks, was expressed at 3.5-fold higher levels in NOD/SCID mice. Cell growth-arrest or senescence genes [eg, *Cdkn1a* (*p21*), transformed mouse 3T3 cell double minute 2 (*Mdm2*), and transformation-related protein 53] were 2- to 100-fold lower in NOD/SCID mice, which was in agreement with less cell damage. Because cyclin C and cyclin D1 levels were 16- and 20-fold higher, respectively, we considered hepatocytes were in G_0/G_1 (ie, their expected state) in NOD/SCID mice. This agreed with absence of hepatic Ki-67 expression (Figure 2B) in NOD/SCID mice because Ki-67 characterizes cells in late G_1 , S, or G_2/M .

Despite differences in stress and toxicity pathways, including several *Cyp* genes, after Rif and Phen for 3 days in NOD/SCID mice, *Cyp3a4* protein was induced (Figure 3), which metabolizes MCT to toxic intermediates.⁶ This was similar to *Cyp3a4* induction in C57BL/6J mice.

Taken together, these findings indicated that, although the baseline pattern of hepatic gene expression in NOD/SCID mice differed from C57BL/6 mice, we did not find evidence for greater ongoing hepatic DNA damage or repair in the former.

Molecular Changes During Rif-Phen-MCT-Induced Hepatic Injury in NOD/SCID Mice

To determine hepatic stress and toxicity pathway genes in NOD/SCID mice after drugs, we used quantitative real-time RT-PCR gene arrays, with healthy NOD/SCID mice as controls. Analysis of tissues from NOD/SCID mice 1, 3, and 7 days after Rif, Phen, and 125-mg/kg MCT showed that, of 84 total genes, 28 to 37 (33%–44%) were expressed at 2-fold higher or lower levels (or more), compared with baseline levels in control mice (Table 2).

After DILI, significant changes occurred in stress and toxicity pathways. For instance, *Cyp2b10* expression increased by 5-fold at 3 day and *Cyp3a11* expression increased by 3-fold at 1 day. Expression of *Cyp2a5*, *Cyp2b9*, and other *Cyp* genes (*1b1*, *4a10*, *4a14*, and *7a1*) declined by 3- to 10-fold or more. Undetectable expression of *Cyp2b9*, *4a14*, and *7a1* was in agreement with perivenous necrosis after Rif-Phen-MCT because these genes are normally expressed there. Among metabolic/oxidative stress genes, glutathione peroxidase 2, glutathione-S-transferase 3, and heme oxygenase 1 were expressed 2- to 16-fold more, whereas expression of the flavin monooxygenases (ie, 1 and 4) declined by 2.5- to 5-fold. Some *Hsp* genes were expressed more, by 2- to 27-fold (eg, *Hspb1*, *Hspa11*, and *Hspa8*); and other *Hsp* genes decreased, typically by 2- to 3-fold (*Dnaja1*, *Hspd1*, and *Hspe1*). These findings indicated that Rif-Phen-MCT caused extensive hepatic oxidative and metabolic stress, although regulation or counterregulation of individual genes was clearly complex.

We observed 3- to 42-fold greater expression of inflammation-associated genes, including C-X-C motif ligand 10, *Il6*, nitric oxide synthase 2, and serine (or cysteine) peptidase inhibitor, clade E, member 1 (Table 2). These genes were expressed at lower levels compared with




Figure 4. Verification of gene expression changes by tissue staining with diaminobenzidine-based methods in Rif-Phen-MCT-treated mice. **A** and **B:** Glutathione-S-transferase 1 (Gstm1) in normal liver, which was lower (**A**) than in drug-treated mice (**B**, inset, cytoplasmic plus nuclear Gstm1). **C** and **D:** The oxidative DNA adducts on guanine residues in occasional cells in normal liver (**C**) and in far more cells in drug-treated mice (**D**, insets, magnified views of cells with adducts, arrows). **E** and **F:** *Atm* in normal liver (**E**) and in drug-treated mice (**F**), where fewer hepatocytes expressed *Atm* and where *Atm* content seemed lower in cells (arrows, insets). **G** and **H:** No p21 expression in normal liver (**G**) and widespread p21 expression in cell nuclei from drug-treated mice (**H**, arrows in inset). Original magnification, $\times 200$. Scale bar = 100 μm . **A** through **C**, **E**, and **F:** Toluidine blue counterstain. **G** and **H:** Eosin counterstain.

NOD/SCID mice versus C57BL/6 mice under basal conditions. By contrast, expression of interleukin-1b and interleukin-18 declined after drugs. The apoptosis genes (ie, annexin A5, BclII-associated X protein, and BclII-like-1) were expressed 2- to 4-fold more, whereas Fas ligand, tumor necrosis factor (ligand) superfamily member 10, and tumor necrosis factor receptor type 1-associated death domain protein were expressed 3- to 10-fold less, in the background of limited terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positivity in liver tissues.

Expression of DNA damage/repair, proliferation, and growth-arrest genes was most remarkable (Table 2). *Atm* expression decreased by 2- to 10-fold (Table 1). Expression of DNA damage/repair genes [ie, *Chek2*, RAD50 homolog (*S cerevisiae*), and *Xrcc4*] declined by 5- to 10-fold. The consequence of these changes should have been inefficient DNA repair, which was verified by analysis of oxidative DNA adducts (explained later). If DNA damage was significant, cell cycling or cell growth should have been perturbed, which was shown by increased *p21* expression (277- to 434-fold), along with cell growth-arrest genes [ie, *Ddit3* (11-fold), growth arrest and DNA damage-inducible 45 α (74-fold), and *Mdm2* (4- to 9-fold)]. The expression of cell cycle proliferation-associated genes (eg, cyclin D1 and *Egr1*) altered by 3- to 10-fold, including no change, decline, or increase in expression; however, *E2f1* expression increased by 2.4-fold after 1 day. This reflected changes in DNA synthesis, as shown by Ki-67 staining at early or later times after drugs (previously described).

We verified the relevance of mRNA level changes by tissue staining. This confirmed hepatic oxidative/metabolic stress because glutathione-S-transferase expression increased (Figure 4, A and B), and extensive oxidative DNA adducts on guanosine residues (Figure 4, C and D) decreased *Atm* expression (Figure 4, E and F) and increased *p21* expression (Figure 4, G and H). These

changes were obvious 1 day after Rif-Phen-MCT and persisted subsequently until death of animals over several days.

Mapping of *Atm* Signaling Pathways

We considered that lower *Atm* expression associated with perturbations in *Atm* targets intimately involved in DNA damage/repair and cell growth arrest indicated roles for *Atm* signaling. Therefore, we mapped genes in curated *Atm* signaling pathways. This showed perturbations in key limbs of *Atm* signaling in NOD/SCID mice after Rif-Phen-MCT-induced liver injury versus control NOD/SCID mice (Figure 5, A and B). In drug-treated mice, markedly increased expression of *p21* and other cell growth-arrest genes suggested that hepatic DNA damage activated cell cycle checkpoint controls, which was consistent with restriction of hepatocytes in G₁, S, or G₂/M, according to Ki-67 staining (Figure 2H).

Taking these findings together, we concluded that gene expression under basal and liver injury conditions in NOD/SCID mice was informative regarding the role of *Atm* signaling in cell growth-arrest in ALF. We then examined cell therapy mechanisms in this mouse model of ALF.

Role of Cell Therapy in Rescuing Animals with ALF and Reversing Molecular Abnormalities

We performed studies to determine whether suitable liver support would permit hepatic repair and regrowth with or without reseeded of the damaged liver with healthy transplanted cells. Because hepatocytes can be transplanted in large numbers in the peritoneal cavity, readily equaling or exceeding those in the liver, we first examined the benefits of graded hepatic support from transplanted cells.




Figure 5. Regulation of *Atm* pathway genes after Rif-Phen-MCT. **A:** Expression of genes in normal liver from the array of 84 genes studied (Table 2 describes gene symbols). Genes in gray boxes were absent from the array studied. Genes in pink boxes were expressed. **B:** Down-regulated genes (green boxes) and up-regulated genes (red boxes) compared with normal liver 3 days after Rif-Phen-MCT. These changes in gene expression were similar 1 or 7 days after drug treatments. In particular, *Atm* expression declined with evidence for impaired protection against DNA damage, leading to activation of p21 and growth-arrest of damaged cells. Specific pathways in differentially expressed gene lists were mapped (PathwayStudio 5.0; Aridane Genomics, Rockville, MD).




Figure 6. Transplanted cell distributions in liver, spleen, and lungs 24 hours after hepatocyte transplantation with microcarriers in the peritoneal cavity. **A** and **B:** Transplanted hepatocytes adjacent to microcarriers (mc) in NOD/SCID mice with GFP immunostaining (green) and merge of GFP plus 4',6-diamidino-2-phenylindole staining of cell nuclei (blue) (**B**). **C, E, and G:** Tissues from donor GFP transgenic mice demonstrating widespread distribution of GFP⁺ cells in the liver, spleen, and lungs. **D, F, and H:** Absence of GFP⁺ cells in the liver, spleen, or lungs. Transplanted cells were also not found in the liver, spleen, and lungs of mice 48 hours or 7 days after transplantation. Original magnification, $\times 200$. Scale bar = 100 μm .

We transplanted 30×10^6 hepatocytes from healthy C57BL/6 donor mice i.p. into some NOD/SCID mice ($n = 6$) and simultaneously treated mice with microcarriers alone ($n = 6$) 2 days after Rif-Phen-MCT administration. Mortality in hepatocyte-treated animals declined significantly over 2 weeks compared with control animals (17% versus 83%; $P < 0.05$).

To verify that transplanted hepatocytes remained in the peritoneal cavity without migrating elsewhere, particularly to the liver, which could have incriminated alternative mechanisms of liver regeneration, we established further groups of NOD/SCID mice 2 days after Rif-Phen-MCT. To localize donor cells, we transplanted i.p. 5×10^6 reporter hepatocytes from GFP donor mice, along with microcarriers. We transplanted GFP donor cells to permit multi-color tissue staining if that were required for characterizing GFP⁺ cells in organs. Tissue analysis from control NOD/SCID mice, donor transgenic mice, and cell recipients 24 or 48 hours after transplantation ($n = 3$ each) showed GFP⁺ transplanted hepatocytes in the peritoneal cavity (Figure 6, A and B). The GFP expression in donor cells was verified in the liver, spleen, and lungs (Figure 6, C, E, and G). However, we did not find GFP⁺ cells in the liver, spleen, or lungs 1, 2, or 7 days after i.p. cell transplantation (Figure 6, D, F, and H), which excluded migra-

tion of intact hepatocytes or redistribution of their fragments by other cells (eg, macrophages).

To determine whether transplantation of xenogeneic cells would have produced similar benefits, which should be of great value for characterizing human cell populations, we next used healthy donor F344 rat hepatocytes. This was also experimentally convenient because only a few hepatocytes may be isolated from mice (typically 30×10^6 to 40×10^6 viable cells per mouse). We administered Rif, Phen, and 125-mg/kg MCT, followed 2 days later by i.p. injection of microcarriers alone ($n = 20$) or 5×10^6 , 10×10^6 , and 50×10^6 rat hepatocytes with microcarriers ($n = 20$). This represented transplantation of 0%, 5%, 10%, and 50%, respectively, of the hepatocyte mass in the mouse liver.

All mice with ALF given microcarriers alone died in 2 weeks, whereas mice treated with rat hepatocytes survived, including after transplantation of only 5×10^6 hepatocytes ($P < 0.001$, log-rank test) (Figure 7A). Therefore, extrahepatic liver support was sufficient for rescuing animals with ALF. We found that mice were healthy 1 day after cell therapy, whereas control mice treated by microcarriers alone worsened with encephalopathy, indicating serious hepatic insufficiency (Figure 7B). In animals with cell therapy, serum bilirubin levels decreased 1, 2, 3, 6, and 8 days after Rif-Phen-MCT to 0.9 ± 0.2 , 1.0 ± 0.2 , 0.8 ± 0.3 , 0.7 ± 0.5 , and 0.8 ± 0.5 mg/dL, respectively (Figure 7C). In control mice given microcarriers alone, the prothrombin time was 2.8 ± 0.4 -fold and 2.9 ± 0.6 -fold above normal after 6 and 8 days, respectively (Figure 7D). By contrast, prothrombin time after cell therapy improved and was only 1.4 ± 0.1 -fold and 1.3 ± 0.3 -fold above normal ($P < 0.05$). Therefore, hepatic support from transplanted hepatocytes in the peritoneal cavity improved critical parameters of liver injury in ALF. Transplanted hepatocytes were identified and were morphologically intact in the peritoneal cavity (Figure 7E). These cells contained glycogen, and glucose-6-phosphatase, which are critical for glucose metabolism (Figure 7F).

To confirm that improved survival in animals was due to intact cells, we established another group of NOD/SCID mice with Rif-Phen-MCT-induced ALF ($n = 10$), in which medium from primary rat hepatocytes cultured in serum-free conditions for 2 days was injected i.p. once daily. This did not alter mortality after ALF, indicating that transplantation of hepatocytes was necessary for rescuing animals with ALF.

Analysis of livers by quantitative real-time RT-PCR arrays in mice 7 days after hepatocyte transplantation in the peritoneal cavity showed that only two genes were differentially expressed (ie, Bcl2l1-associated X protein and *p21*) compared with previous differential expression of 28 genes. Moreover, these two genes were expressed at lower levels compared with mice without cell therapy [ie, 2-fold (Bcl2l1-associated X protein) and 10-fold (*p21*) lower]. This indicated substantial correction of molecular abnormalities in ALF after cell therapy.

To verify that hepatic support by transplanted cells in the peritoneal cavity promoted liver regeneration in ALF, we examined cell cycling by Ki-67 staining. Subsequent to cell transplantation, native hepatocytes were prolifer-




Figure 7. Outcomes in animals with ALF after cell therapy. **A:** Survival curves in mice with ALF after sham treatment with microcarriers alone and reversal of mortality after i.p. transplantation of 1×10^6 F344 rat hepatocytes ($*P < 0.01$, log-rank test). **B:** Encephalopathy in sham-treated mice and its absence in mice treated by transplantation of F344 rat hepatocytes. **C:** Decreases in serum bilirubin levels in treated mice. **D:** Improvements in prothrombin times after cell therapy. All data were from three to five mice per time point. $*P < 0.01$. **E:** Healthy transplanted hepatocytes and microcarriers (mc) in conglomerates recovered after 14 days from the peritoneal cavity (hematoxylin stain). **F:** Histochemical staining showing glycogen in transplanted hepatocytes (pink) adjacent to mc in the peritoneal cavity. Original magnification, $\times 200$. Scale bar = $100 \mu\text{m}$.

ating 3 days, and 6 to 8 days, after the onset of ALF (Figure 8A). The proliferation indices were $5\% \pm 2\%$ and $11\% \pm 4\%$, respectively. This proliferation activity was greater than in animals without cell transplantation at corresponding times, although the differences did not reach statistical significance. Ki-67 was also expressed in bile duct cells (Figure 8B). However, ductular or juxta-ductular cells did not expand to suggest recruitment of stem cells during hepatic recovery. Also, hepatic expres-

sion of *Atm* returned to normal and *p21* was no longer detected by immunostaining (Figure 8, C and D). Liver morphological features were normal after cell therapy for up to 12 weeks.

Finally, to address whether reseeding of the damaged liver with healthy cells would have provided advantages for liver regeneration in ALF, we performed studies with NOD/SCID mice given Rif, Phen, and 125-mg/kg MCT ($n = 30$). To localize transplanted cells in the liver, these studies were performed with Rosa26 donor hepatocytes expressing the *LacZ* gene, which was shown in previous studies to not activate deleterious immune responses in NOD/SCID mice.¹⁸ By contrast, GFP expression in donor transplanted cells activates host immune responses, resulting in clearance of transplanted cells after 7 days, even in NOD/SCID mice. We induced ALF by Rif-Phen-MCT; after 2 days, 2×10^6 Rosa26 donor hepatocytes were transplanted into the liver via the spleen and 5×10^6 F344 rat hepatocytes were simultaneously transplanted into the peritoneal cavity. Once again, all mice treated by cell transplantation survived beyond 14 days, which permitted examination of the time course of transplanted cell engraftment and proliferation.

We observed transplanted *LacZ*⁺ hepatocytes in the liver 1 and 3 days, and 1, 2, 4, and 12 weeks, after cell transplantation ($n = 3$ each). All donor hepatocytes expressed *LacZ*, and cell recipients were negative for *LacZ* (Figure 9, A and B). The *LacZ*⁺ transplanted hepatocytes were in liver sinusoids 1 day after cell transplantation, as was expected, and were integrated in the liver paren-




Figure 8. Changes during hepatic regeneration after cell therapy in mice with ALF. **A and B:** Ki-67 staining 7 days after cell transplantation in the peritoneal cavity alone, indicating proliferation in native hepatocytes (arrows, dark nuclei) and bile duct cells (arrowhead, dark nuclei). **C:** Hepatic *Atm* expression returned to normal at this point. **D:** Absence of *p21* immunostaining in the liver 7 days after transplantation of cells in the peritoneal cavity alone. Original magnification, $\times 200$. Scale bar = $100 \mu\text{m}$. Toluidine blue (A–C) and eosin (D) counterstains were used. Pa, Portal area.




Figure 9. Transplanted hepatocytes in the liver of mice with ALF. **A:** LacZ staining (cytoplasmic blue) in Rosa26 donor liver. **B:** Absence of LacZ staining in recipient NOD/SCID mouse liver. **C and D:** Representative examples of LacZ⁺ transplanted hepatocytes (blue) integrated in the mouse liver 14 days (**C**) or 3 months (**D**) after intrasplenic transplantation. Transplanted hepatocytes are arranged individually, agreeing with absence of their proliferation over time and indicating liver recovery occurred by proliferation of native hepatocytes. Original magnification, $\times 200$. Scale bar = 100 μm . A hematoxylin counterstain was used.

chyma at later times (ie, after 7 or 14 days) (Figure 9C). Transplanted cells survived in the liver throughout the studies, for up to 12 weeks (Figure 9D). Morphometric analysis of the number of transplanted LacZ⁺ cells in the liver showed absence of transplanted cell proliferation because only 2 to 4 transplanted cells were observed in the liver parenchyma adjacent to individual portal areas under all conditions, including after 3 and 7 days and after 1, 2, 4, and 12 weeks. No instances of transplanted cells in clusters were found. This confirmed that liver regenerated by proliferation of native hepatocytes alone after prolongation of survival through hepatic support from transplanted cells in the peritoneal cavity.

Discussion

These studies provide several important insights into the mechanisms of DILI. First, we identified that *Atm* signaling pathways were dysregulated in drug-induced ALF, which, to our knowledge, was not previously known; this offers opportunities for further studies. Second, liver injury induced by Rif-Phen-MCT in NOD/SCID mice reproduced key aspects of ALF in humans, including extensive hepatic necrosis, abnormal liver test results, encephalopathy, coagulopathy, and mortality over several days. Third, this model of ALF provided critical insights into cell therapy mechanisms, particularly by establishing that reseeded the liver with healthy cells was unnecessary. By contrast, metabolic support and perhaps release of paracrine signals from transplanted hepatocytes in the peritoneal cavity permitted native hepatocytes to regenerate the liver in ALF. Fourth, this ALF model in xenotolerant NOD/SCID mice will permit translational studies with candidate human cells, including cells generated from stem cells. This will be of extensive significance for cell therapy in people with ALF.

In the first part, our studies of DILI in NOD/SCID mice reproduced several aspects of APAP-induced changes in oxidative/metabolic stress pathways, including glutathione, heme oxygenase, monooxygenase or *Cyp* genes, *Hsp* genes, cytokines, and other inflammatory mechanisms.¹⁹ This agreed with broad similarities with other drug toxicities. Characterization of liver injury in NOD/SCID mice showed typical manifestations of ALF because of extensive hepatic necrosis, including abnormal liver test results, coagulopathy, and encephalopathy. Moreover, evidence of hepatic DNA synthesis, albeit insufficient for completing liver regeneration, was similar to that in people with ALF.²⁰

In the NOD/SCID setting, deficiencies in DNA repair are driven by mutant catalytic subunit of DNA-dependent protein kinase (*Prkdc*), which is applicable to T and B lymphocytes with a propensity for lymphoma and thymoma.^{21,22} By contrast, *Prkdc* mutation is of no consequence for liver cells. We confirmed this by normal liver test results and hepatic morphological features in healthy control NOD/SCID mice, including absence of apoptosis or of increased Ki-67 expression. Also, studies of liver from healthy NOD/SCID mice by quantitative real-time PCR arrays showed that expression levels of DNA damage-repair and growth-arrest genes were actually lower than in healthy C57BL/6 mice. If lymphocyte deficiency were to impart greater susceptibility for liver injury, this should have been apparent in immunodeficient people. However, in individuals with low levels of lymphocytes, susceptibility to DILI neither increased nor decreased,²³ excluding roles of immunocytes in altering drug hepatotoxicity. The basis of altered gene expression and susceptibility to DILI in NOD/SCID mice (in a C3H/HeJ background) versus C57BL/6 mice likely emanated from strain-dependent genetic and epigenetic regulation of gene expression,²⁴ which essentially reflects individual-specific differences in people.

Although induction of *Cyp3a4* by Rif and other drugs, including Phen and APAP, is thought to worsen hepatotoxicity,^{6,25} we found that Rif and Phen induced *Cyp3a4* in both C57BL/6 and NOD/SCID mice, suggesting drug metabolic differences did not account for outcomes of DILI in these animal strains. Examination of alternative or additional mechanisms led us to *Atm* pathways. The NOD/SCID mice expressed *Atm* at lower levels compared with the C57BL/6 mice. After Rif-Phen-MCT in NOD/SCID mice, *Atm* expression declined further, and greater perturbations in *Atm* signaling were observed in NOD/SCID mice with ALF. Examination of APAP-induced liver gene expression in an experimental study in rats,¹⁹ in which gene expression was determined with limited probe sets 24 hours after APAP, showed 3-fold alterations in oxidative/metabolic stress genes (eg, heme oxygenase 1, *Cyp7a1*, flavin monooxygenase 1, *Hspb1*, *Hspa8*, and *DnaJ*) and in cell proliferation, growth arrest, and senescence genes (eg, *Egr1*, *Ddit3*, growth arrest and DNA damage-inducible 45 α , and *Mdm2*), which was similar to our results herein. These types of data should strengthen the role of *Atm* signaling in other forms of DILI; also, it should be appropriate to consider how regulation

of *Atm* expression may have altered the susceptibility to drug-induced ALF.

Previously, *Atm*^{-/-} mice were shown to have impairment in liver regeneration, including mortality in some cases after partial hepatectomy.²⁶ Similarly, *Atm* deficiency amplified genotoxicity induced by Phen.²⁷ Also, inhibition of *Atm* expression by caffeine, a well-characterized ATM kinase inhibitor,²⁸ significantly increased APAP hepatotoxicity.²⁹ Because expression of *Atm* is largely governed by promoter regulation,³⁰ and is negatively regulated by displacement of positive transcriptional transactivators with soluble factors (eg, epidermal growth factor or hepatocyte growth factor),^{31,32} it should be reasonable to consider whether soluble factors will be relevant in DILI and *Atm* expression and in improvement of *Atm* expression after cell therapy. For instance, positive regulators of *Atm* transcription have also been identified (eg, granulocyte colony-stimulating factor),³⁰ which protects liver from injury by unknown mechanisms.³³ Because multifold increases in *Atm* levels are normally observed during protection of cells from DNA damage,³⁴ lowering of *Atm* levels in Rif-Phen-MCT-treated NOD/SCID mice should have caused serious problems, as represented by multiple perturbations in downstream *Atm* signaling.

The role of *Atm* as master regulator of DNA damage through phosphorylation of multiple effectors is well established.³⁵ After DNA damage, *Atm*, along with other genes (eg, *Chek1* and *Chek2*) phosphorylates *p53*. In turn, *p53* activates *p21*, leading to arrest of damaged cells in G₁/S through corresponding cyclins and cyclin-dependent kinases.³⁶ However, *p21* may also be regulated by *p53*-independent mechanisms.³⁷ We consider it most likely that persistent *Atm* down-regulation in mice after Rif-Phen-MCT led to inadequate DNA repair, as indicated by down-regulation of RAD50 homolog (*S cerevisiae*) and *Xrcc4* genes. This should have recruited *p21*-mediated G₁/S checkpoint arrest. We found that cyclin G, Chek 2, CHK2 checkpoint homolog 1 was up-regulated, whereas cyclin D1, *Egr1*, and *E2F* were up- or down-regulated at various times. Up-regulation of growth arrest and DNA damage-inducible 45α, *Ddit3*, and *Mdm2* provided further evidence for cell growth arrest.³⁸ These mechanisms agreed with our observations of relatively few hepatocytes with Ki-67, which characterizes cells in late G₁, S, and G₂/M.

Previously, only the Mad transcription factor, which dominantly antagonizes the activity of the c-mycelocytomatosis protooncogene, induced ALF through a discrete molecular mechanism, although liver injury was predominantly apoptotic.³⁹ Toxicity through transgenes (eg, pro-drug-activating herpes simplex virus thymidine kinase) produced liver injury, although this damage differed from ALF in people.⁴⁰ By contrast, ALF induced by Rif-Phen-MCT in NOD/SCID mice was similar to the human condition, including extensive hepatic necrosis, liver test abnormalities, encephalopathy, high mortality rates, and the presence of some hepatocytes with DNA synthesis.²⁰

In the second part of this study, we addressed critical cell therapy mechanisms. The ability to rescue subjects with ALF by transplanting cells into the peritoneal cavity

without reseeded of the liver will be of immense clinical significance in view of the simplicity of the former procedure. A few people with ALF have already been treated by transplantation of hepatocytes in the peritoneal cavity,⁴¹ although those studies did not incorporate extracellular matrix support, without which hepatocytes are rapidly destroyed. We found that after cell therapy, abnormalities in hepatic gene expression reversed and liver regeneration was then completed by proliferation in previously growth-arrested native hepatocytes. Cell transplantation experiments with reporter hepatocytes in the liver provided unequivocal evidence for this mechanism. This was in agreement with the possibility that cell proliferation may be restored under appropriate circumstances, despite cell cycle checkpoint-mediated arrest, such as by *p21*.⁴² We excluded migration of transplanted cells from the peritoneal cavity to the native liver or other organs as potential alternative explanations.

As transplanted cells were organized in the peritoneal cavity with liver gene expression, beneficial effects of cell transplantation in ALF included hepatic support from transplanted hepatocytes. Moreover, hepatocytes secrete multiple cytokines, growth factors, and other molecules,⁴³ which could have emanated from transplanted cells in the peritoneal cavity to serve beneficial roles in the recovery of the damaged liver, although further studies of these mechanisms will be appropriate. Soluble factors (eg, granulocyte colony-stimulating factor) restored *Atm* levels in cells through transcriptional control mechanisms.³¹ Injection of cell culture medium did not rescue animals with ALF in our studies. However, this did not exclude the possible role of paracrine factors released by transplanted hepatocytes on other aspects of hepatic recovery.

Finally, this ALF model in NOD/SCID mice will be helpful for defining the therapeutic potential of candidate human stem cell-derived cells because these mice tolerate human xenografts.⁴⁴ Studies of additional mechanisms regulating liver regeneration in ALF should also be of great value.

References

- Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D: Drug-related hepatotoxicity and acute liver failure. *J Pediatr Gastroenterol Nutr* 2008, 47:395–405
- Jaeschke H: Innate immunity and acetaminophen-induced liver injury: why so many controversies? *Hepatology* 2008, 48:699–701
- Avraham Y, Grigoriadis NC, Magen I, Poutahidis T, Vorobiev L, Zolotarev O, Ilan Y, Mechoulam R, Berry EM: Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice. *Br J Pharmacol* 2009, 158:896–906
- Bémeur C, Vaquero J, Desjardins P, Butterworth RF: N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. *Metab Brain Dis* 2010, 25:241–249
- Shinohara M, Ybanez MD, Win S, Than TA, Jain S, Gaarde WA, Han D, Kaplowitz N: Silencing glycogen synthase kinase-3β inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. *J Biol Chem* 2010, 285:8244–8255
- Wu YM, Joseph B, Berishvili E, Kumaran V, Gupta S: Hepatocyte transplantation and drug-induced perturbations in liver cell compartments. *Hepatology* 2008, 47:279–287

7. Fisher RA, Strom SC: Human hepatocyte transplantation: worldwide results. *Transplantation* 2006, 82:441–449
8. Gupta S, Rajvanshi P, Irani AN, Palestro CJ, Bhargava KK: Integration and proliferation of transplanted cells in hepatic parenchyma following D-galactosamine-induced acute injury in F344 rats. *J Pathol* 2000, 190:203–210
9. Gupta S, Vemuru RP, Lee C-D, Yerneni P, Aragona E, Burk RD: Hepatocytes exhibit superior transgene expression after transplantation into liver and spleen compared with peritoneal cavity or dorsal fat pad: implications for hepatic gene therapy. *Human Gene Ther* 1994, 5:959–967
10. Rajvanshi P, Kerr A, Bhargava KK, Burk RD, Gupta S: Studies of liver repopulation using the dipeptidyl peptidase IV deficient rat and other rodent recipients: cell size and structure relationships regulate capacity for increased transplanted hepatocyte mass in the liver lobule. *Hepatology* 1996, 23:482–496
11. Gupta S, Rajvanshi P, Malhi H, Sokhi RP, Slehria S, Vasa SRG, Dabeva M, Shafritz DA, Kerr A: Cell transplantation causes loss of gap junctions and activates GGT expression permanently in host liver. *Am J Physiol Gastroint Liver Physiol* 2000, 279:G815–G826
12. Slehria S, Rajvanshi P, Ito Y, Sokhi RP, Bhargava KK, Palestro CJ, McCuskey RS, Gupta S: Hepatic sinusoidal vasodilators improve transplanted cell engraftment and ameliorate microcirculatory perturbations in the liver. *Hepatology* 2002, 35:1320–1328
13. Joseph B, Malhi H, Bhargava KK, Palestro CJ, McCuskey RS, Gupta S: Kupffer cells participate in early clearance of syngeneic hepatocytes transplanted in the rat liver. *Gastroenterology* 2002, 123:1677–1685
14. Krohn N, Kapoor S, Enami Y, Follenzi A, Bandi S, Joseph B, Gupta S: Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. *Gastroenterology* 2009, 136:1806–1817
15. Demetriou AA, Whiting JF, Feldman D, Levenson SM, Chowdhury NR, Moscioni AD, Kram M, Chowdhury JR: Replacement of liver function in rats by transplantation of microcarrier-attached hepatocytes. *Science* 1986, 233:1190–1192
16. Kumaran V, Bente D, Follenzi A, Joseph B, Sarkar R, Gupta S: Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. *J Thromb Haemost* 2005, 3:2022–2031
17. Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, National Academy Press, Washington, D.C., 1996.
18. Gagandeep S, Ott M, Sokhi R, Gupta S: Rapid clearance of syngeneic transplanted hepatocytes following transduction with E-1-deleted adenovirus indicates early host immune responses and offers novel ways for studying viral vector, target cell and host interactions. *Gene Ther* 1999, 6:729–736
19. Morishita K, Mizukawa Y, Kasahara T, Okuyama M, Takashima K, Toritsuka N, Miyagishima T, Nagao T, Urushidani T: Gene expression profile in liver of differing ages of rats after single oral administration of acetaminophen. *J Toxicol Sci* 2006, 31:491–507
20. Quaglia A: Auxiliary transplantation for acute liver failure: histopathological study of native liver regeneration. *Liver Transpl* 2008, 14:1437–1448
21. Fulop GM, Phillips RA: The scid mutation in mice causes a general defect in DNA repair. *Nature* 1990, 347:479–482
22. Jhappan C, Morse HC 3rd, Fleischmann RD, Gottesman MM, Merlino G: DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. *Nat Genet* 1997, 17:483–486
23. De Lazzari E, León A, Arnaiz JA, Martinez E, Knobel H, Negro E, Clotet B, Montaner J, Storfer S, Asenjo MA, Mallolas J, Miró JM, Gatell JM: Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. *HIV Med* 2008, 9:221–226
24. Geisert EE, Lu L, Freeman-Anderson NE, Templeton JP, Nassr M, Wang X, Gu W, Jiao Y, Williams RW: Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice. *Mol Vis* 2009, 15:1730–1763
25. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ: Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. *Drug Metab Dispos* 2009, 37:1611–1621
26. Lu S, Shen KC, Wang Y, Brooks SC, Wang YA: Impaired hepatocyte survival and liver regeneration in Atm-deficient mice. *Hum Mol Genet* 2005, 14:3019–3025
27. Bhuller Y, Jeng W, Wells PG: Variable in vivo embryoprotective role for ataxia-telangiectasia-mutated against constitutive and phenytoin-enhanced oxidative stress in Atm knockout mice. *Toxicol Sci* 2006, 93:146–155
28. Ravi D, Muniyappa H, Das KC: Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKdelta-p38 MAPK-dependent mechanism. *Mol Cell Biochem* 2008, 308:193–200
29. Sato C, Izumi N: Mechanism of increased hepatotoxicity of acetaminophen by the simultaneous administration of caffeine in the rat. *J Pharmacol Exp Ther* 1989, 248:1243–1247
30. Gueven N, Keating K, Fukao T, Loeffler H, Kondo N, Rodemann HP, Lavin MF: Site-directed mutagenesis of the ATM promoter: consequences for response to proliferation and ionizing radiation. *Genes Chromosomes Cancer* 2003, 38:157–167
31. Gueven N, Keating KE, Chen P, Fukao T, Khanna KK, Watters D, Rodemann PH, Lavin MF: Epidermal growth factor sensitizes cells to ionizing radiation by down-regulating protein mutated in ataxia-telangiectasia. *J Biol Chem* 2001, 276:8884–8891
32. Maroni P, Bendinelli P, Matteucci E, Desiderio MA: GF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. *Carcinogenesis* 2007, 28:267–279
33. Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S: Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. *Toxicol Lett* 2009, 187:40–44
34. Gatei M, Young D, Cerosaletti KM, Desai-Mehta A, Spring K, Kozlov S, Lavin MF, Gatti RA, Concannon P, Khanna K: ATM-dependent phosphorylation of nibrin in response to radiation exposure. *Nat Genet* 2000, 25:115–119
35. Kanu N, Behrens A: ATMINstrating ATM signalling: regulation of ATM by ATMIN. *Cell Cycle* 2008, 7:3483–3486
36. Kuribayashi K, El-Deiry WS: Regulation of programmed cell death by the p53 pathway. *Adv Exp Med Biol* 2008, 615:201–221
37. Li DQ, Pakala SB, Reddy SD, Ohshiro K, Peng SH, Lian Y, Fu SW, Kumar R: Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. *J Biol Chem* 2010, 285:10044–10052
38. Zhang J, Chen X: Posttranscriptional regulation of p53 and its targets by RNA-binding proteins. *Curr Mol Med* 2008, 8:845–849
39. Gagandeep S, Sokhi R, Slehria S, Gorla GR, Furguele J, DePinho RA, Gupta S: Hepatocyte transplantation improves survival in mice with liver toxicity induced by hepatic overexpression of Mad1 transcription factor. *Mol Ther* 2000, 1:358–365
40. Braun KM, Degen JL, Sandgren EP: Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells. *Nat Med* 2000, 6:320–326
41. Habibullah CM, Syed IH, Qamar A, Taher-Uz Z: Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. *Transplantation* 1994, 58:951–952
42. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV: Rapamycin decelerates cellular senescence. *Cell Cycle* 2009, 8:1888–1895
43. Rowell DL, Eckmann L, Dwinell MB, Carpenter SP, Raucy JL, Yang SK, Kagnoff MF: Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion. *Am J Physiol* 1997, 273:G322–G332
44. Cho J, Joseph B, Sappal BS, Giri RK, Wang R, Ludlow J, Susick R, Gupta S: Analysis of the functional integrity of cryopreserved human liver cells including xenografting in immunodeficient mice to address suitability for clinical applications. *Liver Int* 2004, 24:361–370